Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J0896
    Short Description Inj luspatercept-aamt 0.25mg
    Long Description Injection, luspatercept-aamt, 0.25 mg
    Pricing indicator 51
    Coverage code C
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2020-07-01
    Date Added 2020-07-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    59572071101 J0896 Inj luspatercept-aamt 0.25mg Reblozyl CELGENE CORPORATION 0.25 MG 1 1 100 100
    59572077501 J0896 Inj luspatercept-aamt 0.25mg Reblozyl CELGENE CORPORATION 0.25 MG 1 1 300 300
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    Drug Details

    • Luspatercept-aamt injection is used to treat anemia (a lower than normal number of red blood cells) in adults who are receiving blood transfusions to treat thalassemia (an inherited condition that causes a low number of red blood cells). Luspatercept-aamt injection is also used to treat anemia in adults with certain types of myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells) and who are receiving blood transfusions, but have not responded to or cannot receive treatment with an erythropoiesis-stimulating agent (ESA). Luspatercept-aamt is in a class of medications called erythroid maturation agents. It works by increasing the number and quality of red blood cells.